FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medications for prevention or relief of poisoning by large clostridial cytotoxins (LCT), in particular toxins A and B (TcdA, TcdB) Clostridium difficile, which characterised by containing as active substance, at least, one effector, namely inhibitor or activator of autocatalytic activity of protease of cytotoxins LCT.
EFFECT: group of inventions ensures efficient suppression of infections caused by Clostridium difficile toxins.
20 cl, 6 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS RELEVANT TO MUTANT TOXIN FROM CLOSTRIDIUM DIFFICILE | 2013 |
|
RU2630671C2 |
| COMPOSITIONS RELATED TO CLOSTRIDIUM DIFFICILE MUTANT TOXIN, AND METHODS OF APPLICATION THEREOF | 2012 |
|
RU2592686C2 |
| ANTIBODIES FOR TREATMENT OF INFECTION AND DISEASES ASSOCIATED WITH CLOSTRIDIUM DIFFICILE | 2011 |
|
RU2630663C9 |
| METHOD OF DNA AMPLIFICATION ON BASIS OF INCORPORATION INTO CHAIN | 2014 |
|
RU2673733C2 |
| METHOD OF DETECTION AND CHARACTERIZATION OF TOXINOGENIC STRAIN CLOSTRIDIUM DIFFICILE | 2010 |
|
RU2612789C2 |
| HUMAN ANTIBODIES TO CLOSTRIDIUM DIFFICILE TOXINS | 2013 |
|
RU2628305C2 |
| METHODS AND COMPOSITIONS FOR INDUCTION OF IMMUNE RESPONSE AGAINST CLOSTRIDIUM DIFFICILE | 2018 |
|
RU2781057C2 |
| HUMAN GENETIC MARKERS ASSOCIATED WITH RESPONSE TO TREATMENT AGENTS THAT TARGET TOXIN B CLOSTRIDIUM DIFFICILE | 2017 |
|
RU2761249C2 |
| METHOD OF PRODUCING PROTEOLYTICALLY PROCESSED POLYPEPTIDE | 2012 |
|
RU2673910C2 |
| RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
